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Abstract
Background: Arteriosclerosis (arterial stiffening) is associated with future cardiovascular events, with this effect
postulated to be due to its effect on cardiac afterload, atherosclerosis (plaque formation) progression or both, but
with limited evidence examining these early in disease formation. The aim of the current study is to examine the
association between arteriosclerosis, atherosclerosis and ventricular remodelling in a population at low-intermediate
cardiovascular risk.
Methods: One thousand six hundred fifty-one subjects free of clinical cardiovascular disease and with a < 20%
10 year cardiovascular risk score underwent a cardiovascular magnetic resonance (CMR) study and whole body CMR
angiogram. Arteriosclerosis was measured using total arterial compliance (TAC) - calculated as the indexed stroke
volume divided by the pulse pressure. Atherosclerosis was quantified using a standardised atheroma score (SAS)
which was calculated by scoring 30 arterial segments within the body based on the degree of stenosis, summating
these scores and normalising it to the number of assessable segments. Left ventricular remodelling was measured
using left ventricular mass to volume ratio (LVMVR).
Results: One thousand five hundred fifteen (38% male, 53.8 ± 8.2 years old) completed the study. On univariate
analysis TAC was associated with SAS but this was lost after accounting for cardiovascular risk factors in both males
(B = − 0.001 (− 0.004–0.002),p = 0.62) and females (B = 0.000(95%CI -0.002–0.002),p = 0.78). In contrast compliance
correlated with LVMVR after accounting for cardiovascular risk factors (B = − 0.12(95%CI -0.16–0.091),p < 0.001 in
males; B = − 0.12(95%CI -0.15–0.086),p < 0.001 in females).
Conclusion: Systemic arteriosclerosis is associated with left ventricular remodelling but not atherosclerosis. Future efforts
in cardiovascular risk prevention should thus seek to address both arteriosclerosis and atherosclerosis individually.
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Background
Arteriosclerosis is the stiffening of the arterial wall,
which occurs with advancing age and is strongly associ-
ated with major adverse cardiovascular events [1]. It is
predominantly a product of age and pulse pressure,
reflecting the repetitive strain of the pulsatile cardiac
output on the elastic fibres of the arterial wall. While its
association with cardiovascular morbidity and mortality is
well established, the exact pathophysiological mechanisms
by which it exerts this effect are not entirely clear [2]. The
key pathophysiological process underpinning cardiovascu-
lar disease is the formation, progression and rupture of
atherosclerotic plaque. Increased arterial stiffness has been
linked to reduced wall shear stress and thereby may be an
antecedent event to the formation of atherosclerotic pla-
ques [3]. Alternatively it may be that, other than the aging
process, arteriosclerosis and atherosclerosis are autono-
mous risk variables, exerting independent adverse effects
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on the cardiovascular system and thus requiring individual
therapeutic targetting.
Previous work has demonstrated mixed results be-
tween coronary artery calcification and carotid plaque
and arterial stiffness [4–6]. However a limitation of these
techniques is their focus on a single arterial territory.
Atherosclerosis is a systemic disease, thus absence of
plaque in one territory does not equate to absence of
plaque in another [7, 8]. Whole body cardiovascular mag-
netic resonance angiography (WB-CMRA) allows sys-
temic quantification of the global atherosclerosis burden
within the body, with the results of this showing strong
prognostic capabilities for future adverse cardiovascular
events [9–11]. Thus the aim of the current study was to
compare early atherosclerotic plaque formation and arter-
ial stiffening in a non-high risk cohort with no prior diag-
nosis of cardiovascular disease, to test the hypothesis that
increased arterial stiffening would be associated with an
increased atherosclerotic plaque burden.
Methods
Study population
Four thousand four hundred twenty-three participants
were recruited to the Tayside Screening for Cardiovascu-
lar Events (TASCFORCE) study from which 2047 sub-
jects were recruited to the imaging arm (see CONSORT
diagram (Fig. 1) for full details) [12]. Subjects were en-
rolled if they were: (i) ≥40 years old; (ii) clinically and
symptomatically free of cardiovascular disease; (iii) had a
serum brain natriuretic peptide (BNP) level greater than
their gender specific median; and (iv) had a ten-year risk
of coronary heart disease < 20% as predicted by the
Adult Treatment Panel III (ATPIII) algorithm [13].
Exclusion criteria included: (i) pregnancy; (ii) known car-
diovascular disease; (iii) known primary muscle disease;
(iv) active liver disease (these latter two due to a pro-
posed later planned study with statins); (v) known dia-
betes; (vi) other known illness or contraindication to
CMR; (vii) participation in a clinical trial; (viii) inability
to give informed consent; (ix) known alcohol abuse; and
(x) a blood pressure of greater than 145/95 mmHg.
Image acquisition
The CMR protocol has been described in detail else-
where [14], but in brief, imaging was performed using a
3 T system (Magnetom Trio, Siemens Healthineers,
Erlangen, Germany). WB-CMRA was performed using a
dual bolus injection technique a CMR cine sequences
performed before the first contrast injection.
For WB-CMRA acquisition, the body was divided into
4 stations to cover the entire arterial tree: 1) Head, neck
and thorax; 2) Abdomen and pelvis; 3) Thighs; and 4)
Peripheral run off. Following the injection of the first
bolus of 10 ml of 0.5 mmol/ml gadoterate meglumine
(Dotarem, Guerbet, Villepinte, France) followed by
20 ml saline injected at a rate of 1.5 ml/s, acquisition of
the head, neck and thoracic station was acquired using a
3D TurboFLASH sequence. This was rapidly followed
by three sequential acquisitions of the calf vessels after
completion of the thoracic station to account for
variable arterial transit times to the distal leg vessels.
Following a short delay the second dose of 15 ml of
gadoterate meglumine was infused at 1.5 ml/s followed
by a 20 ml saline flush with acquisition of the two
stations covering the abdominopelvic and thigh vessels.
Figure 2 demonstrates examples of whole body angio-
grams of two participants with a normal standardized
atheroma score (SAS) and a high SAS.
For CMR, a body matrix radiofrequency (RF) coil
(6 elements) was used in combination with a spine array
(up to 24 elements). ECG-gated segmented breath-hold
cinematic (cine) TrueFISP images were acquired in the
horizontal and vertical long axes, and in the short axis from
the atrio-ventricular ring to the LV apex using 2D
ECG-gated breath-hold segmented cine TrueFISP sequence.
Image analysis
WB-CMRA images were analyzed by one of four blinded
observers on standard image analysis workstations
(using Carestream PACS v10.1 on Barco 3MP monitors,
Barco, Belgium) using the original source post-contrast
images, along with subtracted multiplanar reformats and
maximum intensity projections. The whole-body arterial
Fig. 1 CONSORT diagram for the TASCFORCE study
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tree for every patient was divided anatomically into 31
segments: right and left internal carotid arteries; right
and left vertebral arteries; right and left common carotid
arteries; innominate artery; right and left subclavian ar-
teries; aortic arch; thoracic aorta; abdominal aorta;
coeliac artery; superior mesenteric artery; inferior mes-
enteric artery; right and left renal arteries; right and left
iliac arteries; right and left femoral arteries; right and left
profunda femoris arteries; right and left popliteal arteries;
right and left anterior tibial arteries; right and left peroneal
arteries; and right and left posterior tibial arteries. Each ar-
terial segment was visually assessed for the region of
greatest stenosis. According to the degree of this stenosis
each vessel was scored from 0 to 4: 0 = Disease-free vessel;
1 = < 50% stenosis; 2 = 50–70% stenosis; 3= > 70% stenosis;
and 4 = Vessel occlusion. Arterial segments which were
not visualised with sufficient clarity for grading of the
degree of stenosis were not analysed.
Atherosclerotic plaque burden was quantified using a
standardised atheroma score (SAS). To calculate this,
the score of the 30 arterial segments was summated and
then, to account for the fact that not all vessels could be
scored in all participants, the final score was divided by
the number of segments which had been successfully ana-
lyzed (n), and then calculated as a percentage of the max-
imum possible stenosis score (see equation below) [15].
SAS ¼ Σ vessel scores
n
 
 1
4
 
 100
The reproducibility of this scoring technique has been
previously reported based on the analysis of 48 scans
randomly selected by the trial statistician with excellent
intra- and inter-observer agreement [14].
Left ventricular (LV) mass and volume quantification
was performed as previously described [14]. LV mass
and volumes were indexed to body surface area (calcu-
lated using the Dubois and Dubois formula). LV mass:
volume ratio (LVMVR) was calculated using non-
indexed values as previously described. As LVMVR is
the earliest ventricular remodeling response to increased
cardiac stress and afterload as well as its independence
from the distorting effects of allometric assumptions in
indexing, this was used as the index variable with which
to examine the effects of atherosclerosis and arterioscler-
osis on cardiac remodeling [16].
Compliance calculation
Arteriosclerosis was measured using total arterial com-
pliance (TAC). This was calculated using the brachial
pulse pressure (systolic blood pressure – diastolic blood
pressure) and the CMR calculated indexed stroke vol-
ume using the following equation:
Compliance ¼ Pulse pressure
indexed Stroke Volume
Statistical analysis
Data are expressed as mean ± standard deviation (SD)
for continuous variables, median (range) for ordinal vari-
ables and N (%) for nominal variables. Normality tests
were performed; if the test failed, where possible
Fig. 2 Whole body cardiovascular magnetic resonance angiograms
(WB-CMRA) demonstrating (a) a normal study free from atherosclerosis
(a) and b) a study with extensive low grade atherosclerosis with stenosis
of the right carotid bulb (open arrow head), aorta (closed arrow head)
and left external iliac artery (triangle)
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standard transformations such as square root, reciprocal
or logarithmic transforms were used to generate a
Gaussian distribution. To test the null hypothesis that
samples originate from the same population an inde-
pendent t-test was used for continuous variables. Chi-
square or Fisher exact test were used as appropriate to
compare nominal data. Spearman rank correlation co-
efficient was used to determine the association between
TAC, SAS and LVMVR. Multivariable linear regression
analyses were performed for TAC, SAS, and LVMVR.
For all 3 linear regressions the dependant variable (TAC,
SAS, and LVMVR in turn) were log transformed (a con-
stant of 1 was added to the SAS before log transform-
ation to avoid logging values of 0). Independence of
residuals was confirmed in all instances using the
Durbin-Watson statistic. Linearity was confirmed using
scatter plots, as was homoscedasticity as assessed by vis-
ual inspection of a plot of studentised residuals versus
unstandardized predicted values. In all 3 linear regres-
sion models there was significant collinearity of choles-
terol and LDL, therefore total cholesterol was excluded
from the multiple linear regression model. The Scottish
Index of Multiple Deprivation (SIMD) [17] was treated
as a continuous variable within the model. Due to the
known significant differences in cardiac mass and vol-
umes between genders, analysis was conducted separ-
ately for men and women [18]. As the hypertension
guidelines have changed substantially since the study
was conceived when a blood pressure of < 145/95 was
considered normotensive, a sensitivity analysis was per-
formed to determine if the results hold true in a cohort
who would continue to be considered normotensive ac-
cording to the 2017 AHA/ACC guidelines (BP < 120/80)
[19]. All data were analysed using SPSS (version 21.0,
International Business Machines, Inc., Armonk, New
York, USA. Significance was assumed when p < 0.05.
Results
Of the 2047 participants eligible for and offered a CMR
scan, 1528 (74.8% of those invited) completed or partially
completed the scan protocol with 13 (1%) excluded due to
missing or incomplete data, leaving 1515 in the final
analysis. 373 (18.2%) did not consent for a scan and 12
(0.6%) failed to attend their CMR scan appointment. 101
participants (4.9%) were not scanned due to claustropho-
bia (n = 83), large body habitus (n = 3), inability to estab-
lish venous access/other technical issues (n = 15), or being
unsafe to scan due to presence of metalwork (n = 34).
Of the final 1515, 574 were male (53.8 ± 8.2 years old)
and 941 were female (54.3 ± 8.4 years old). The male
population had a significantly higher systolic and diastolic
blood pressure, a higher body mass index (BMI), a lower
total cholesterol driven by lower HDL-cholesterol, higher
random blood glucose, lower BNP, higher LV mass,
LVMVR and compliance (p < 0.05 for all) (Table 1). There
was no significant difference in SAS between males and
females.
Arteriosclerosis
In men: age, heart rate, systolic and diastolic blood pres-
sure, low density lipoprotein (LDL) cholesterol, and so-
cioeconomic deprivation were independently associated
with TAC (model R2 = 0.67, p < 0.001). In women: age,
heart rate, systolic and diastolic blood pressure, BMI, tri-
glycerides, and smoking pack years were independently
associated with TAC (model R2 = 0.67, p < 0.001) (See
Table 2 for full results of multivariable linear regression).
While there was a mild correlation between TAC and
SAS (see Fig. 3), in neither males nor females was there
a significant independent association between TAC and
SAS. In the subgroup meeting current normotensive cri-
teria only the associations between TAC and heart rate,
systolic and diastolic blood pressure remained for both
males and females (Additional file 1: Table S1).
Atherosclerosis
In men: age, BMI, and smoking pack-years were inde-
pendently associated with the SAS (model R2 = 0.17, p <
0.001). In women: age and smoking pack years were in-
dependently associated with the SAS (model R2 = 0.67,
p < 0.001) (See Table 3 for full results of multivariable
linear regression). In neither males nor females was
there a significant independent association between SAS
and TAC. In the subgroup meeting current normoten-
sive criteria only the associations between SAS and age
and smoking pack years remained for both males and
females (Additional file 1: Table S2).
Left ventricular remodelling
In men: systolic and diastolic blood pressure, current
smoking status, BMI, TAC and SAS were independently
associated with LVMVR (model R2 = 0.19, p < 0.001). In
women: age, systolic and diastolic blood pressure, LDL-
cholesterol, current smoking status, smoking pack years,
BMI and TAC were independently associated with
LVMVR (model R2 = 0.23, p < 0.001) (See Table 4 for full
results of multivariable linear regression). In the subgroup
meeting current normotensive criteria, the majority of
these associations was lost in men with only TAC
remaining as the only significant correlation with LVMVR,
in women the association between LVMVR and age,
systolic and diastolic blood pressure, LDL-cholesterol,
BMI and TAC remained (Additional file 1: Table S3).
Discussion
In the current study we have shown: 1) that arterioscler-
osis and atherosclerosis have different risk factors; 2)
that when cardiovascular risk factors are accounted for,
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arteriosclerosis and atherosclerosis show no significant
association with each other; and 3) arteriosclerosis is as-
sociated with early LV remodelling.
Studies examining the link between atherosclerosis
and arteriosclerosis have produced mixed results. The
Rotterdam study showed a significant link between pulse
Table 1 Characteristics of the total cohort and by sex
Total Men Women p-value
N 1515 574 941
Age (years) 54.1 ± 8.3 53.8 ± 8.2 54.3 ± 8.4 0.24
Heart rate (bpm) 63.4 ± 10.0 61.4 ± 9.7 64.6 ± 9.9 < 0.001
Systolic BP (mmHg) 122 ± 12 125 ± 11 121 ± 12.5 < 0.001
Diastolic BP (mmHg) 73 ± 9 75 ± 9 72 ± 9 < 0.001
BMI (kg/m2) 26.8 ± 4.3 27.1 ± 3.6 26.6 ± 4.6 0.025
Current smoker (%) 165 (10.9%) 51 (8.9%) 114 (12.1%) 0.057
Ex smoker (%) 414 (27.4%) 162 (28.3%) 252 (26.8%) 0.52
Non-smoker (%) 935 (61.8%) 360 (62.8%) 575 (61.1%) 0.53
Smoking pack years 6.03 ± 11.9 6.64 ± 13.7 5.65 ± 10.6 0.12
Family history of CVD 387 (25.5%) 131 (22.8%) 256 (27.2%) 0.058
Total cholesterol (mmol/L) 5.48 ± 0.97 5.40 ± 0.92 5.53 ± 1.0 0.016
LDL-Cholesterol (mmol/L) 3.40 ± 0.88 3.40 ± 0.83 3.39 ± 0.90 0.83
HDL-Cholesterol (mmol/L) 1.44 ± 0.43 1.25 ± 0.39 1.56 ± 0.41 < 0.001
Triglycerides (mmol/L) 1.47 ± 0.86 1.71 ± 0.96 1.32 ± 0.75 < 0.001
Random glucose (mmol/L) 5.18 ± 0.90 5.27 ± 0.78 5.11 ± 0.97 0.018
BNP (pg/ml) 27.4 ± 17.9 19.8 ± 13.7 32.1 ± 18.5 < 0.001
ASSIGN risk score (%) 9.3 ± 6.6 11.4 ± 6.5 7.9 ± 6.3 < 0.001
LVEDV (g/m2) 71.6 ± 12.4 77.3 ± 13.2 68.1 ± 10.5 < 0.001
LVESV (g/m2) 22.6 ± 7.1 25.0 ± 7.4 21.1 ± 6.6 < 0.001
LVSV (g/m2) 49.0 ± 8.3 52.2 ± 8.9 47.0 ± 7.2 < 0.001
LVEF (%) 68.8 ± 6.5 67.9 ± 6.2 69.3 ± 6.6 < 0.001
LV mass (g/m2) 55.1 ± 11.6 64.3 ± 10.6 49.5 ± 8.0 < 0.001
LVMVR (g/ml) 0.78 ± 0.15 0.85 ± 0.16 0.74 ± 0.13 < 0.001
Compliance (ml/m2/mmHg) 1.03 ± 0.28 1.17 ± 1.96 0.99 ± 0.27 < 0.001
SAS 1.27 ± 2.1 1.17 ± 1.96 1.34 ± 2.18 0.14
SIMD
1 65 (4.3%) 20 (2.1%) 45 (4.8%) 0.72
2 78 (5.2%) 25 (4.4%) 53 (5.7%)
3 101 (6.7%) 36 (6.3%) 65 (6.9%)
4 77 (5.1%) 34 (5.9%) 43 (4.6%)
5 93 (6.2%) 34 (5.9%) 59 (6.3%)
6 165 (10.9%) 63 (11%) 102 (10.9%)
7 246 (16.3%) 88 (15.3%) 158 (16.8%)
8 295 (19.5%) 115 (20%) 180 (19.2%)
9 275 (18.2%) 109 (19%) 166 (17.7%)
10 117 (7.7%) 50 (3.3%) 67 (7.1%)
ASSIGN Assessing cardiovascular risk using SIGN guidelines, BMI body mass index, BNP brain natriuretic peptide, BP blood pressure, CVD cardiovascular disease,
HDL high density lipoprotein, LDL low density lipoprotein, LVEDV left ventricular end diastolic volume, LVESV left ventricular end systolic volume, LVSV left
ventricular stroke volume, LVEF left ventricular ejection fraction, LVMVR left ventricular mass to volume ratio, SAS standardised atheroma score, SIMD Scottish Index
of Multiple Deprivation
P-values < 0.05 highlighted in bold
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wave velocity (PWV) – a measure of arterial stiffening -
and aortic arterial calcification [20], however a twin
study showed that while PWV was associated with aortic
wall calcification this was mediated by genetic factors
and that PWV was not linked to plaque burden [21].
Previous work in 306 seventy-year-olds in the PIVUS
(Prospective Investigation of the Vasculature in Uppsala
Seniors) study found a correlation between the total ath-
erosclerotic burden as measured on whole body angiog-
raphy and the carotid arterial distensibility and the
stroke-volume to pulse pressure ratio [22]. However this
study suffered from several limitations: it did not stratify
by sex, a known confounder for stroke volume and pulse
pressure; and did not index the stroke volume thus
opening the study to significant confounding from body
size [18]. Indeed previous work has shown compliance
calculated using indexed SV but not unadjusted SV to
be an independent predictor for cardiovascular events
demonstrating the importance of these adjustments [23].
A study by Sawabe et al. who conducted post mortem
examinations in 304 individuals with a pre mortem
PWV showed a weak correlation between the PWV and
atherosclerotic plaque burden (spearman rho = 0.32)
which persisted after accounting for age and systolic
blood pressure, but did not attempt to account for other
risk factors [24]. Thus the lack of correlation in our
current study compared to those of the Sawabe group
may be due to a lack of correction for other confounding
variables such as BMI or smoking both of which we have
shown to be correlated with arteriosclerosis and athero-
sclerosis respectively. Further supportive evidence of our
results comes from a previous study on coronary plaque
volume on intravascular ultrasound showing no signifi-
cant correlation with carotid femoral pulse wave velocity
[25]. Similarly another Rotterdam study showed a sig-
nificant correlation between carotid plaque and aortic
PWV which was lost after adjusting for cardiovascular
risk factors [6]. Limitations of these latter studies is their
correlation of one regional measure of arterial stiffness
with plaque volume measured in a separate region, how-
ever atherosclerosis in one region poorly correlates with
disease in other regions [8, 26]. In addition these studies
examined populations at high risk for or with known
cardiovascular disease. This is the first study to look at
those without established cardiovascular disease and
without high risk for the development of cardiovascular
disease providing key insights into early disease forma-
tion. Thus it is feasible that in advanced disease, in-
creased arterial stiffness could interact with existing
plaque to accelerate its growth or reduce its stability.
The finding of a significant correlation between
systemic arterial stiffness and left ventricular remodeling
is in agreement with that of MESA (MultiEthnic Study
of Atherosclerosis), who also found a significant increase
in the LVMVR ratio with increasing arterial stiffness
[27]. Given the known importance of the LVMVR in its
prediction of future cardiovascular events [28], this pro-
vides further weight to this being a significant mechan-
ism by which arterial stiffness exerts its effects on future
cardiovascular risk.
Our systemic approach to the assessment of these two
separate entities and our observations are both novel and
Table 2 Backward multivariable linear regression of (log) TAC for each sex
Men Women
B (95% CI) p B (95% CI) p
Age (years) −0.001 (− 0.002- -0.000) 0.004 − 0.001 (− 0.002- -0.001) < 0.001
Heart rate (bpm) − 0.003 (− 0.003 - − 0.002) < 0.001 -0.002 (− 0.002 - -0.001) < 0.001
Systolic BP (mmHg) −0.008 (− 0.009- − 0.008) < 0.001 -0.008 (− 0.009- -0.008) < 0.001
Diastolic BP (mmHg) 0.009 (0.008–0.010) < 0.001 0.009 (0.008–0.009) < 0.001
BMI (kg/m2) 0.001 (− 0.002–0.001) 0.62 −0.001 (− 0.002–0.000) 0.028
LDL-Cholesterol (mmol/L) − 0.007 (− 0.014–0.000) 0.047 −0.005 (− 0.010–0.001) 0.078
HDL-Cholesterol (mmol/L) 0.016 (− 0.002–0.033) 0.077 0.000 (− 0.12–0.12) 0.95
Triglycerides (mmol/L) −0.002 (− 0.009–0.006) 0.67 −0.009 (− 0.016 - -0.002) 0.011
Smoking status 0.001 (−0.010–0.013) 0.80 0.005 (− 0.004–0.013) 0.29
Pack years 0.000 (−0.001–0.00) 0.56 − 0.001 (− 0.001–0.00) 0.011
Family history of CVD − 0.009 (− 0.023–0.005) 0.23 0.005 (− 0.005–0.015) 0.36
SIMD −0.003 (− 0.005- − 0.001) 0.016 0.001 (− 0.001–0.003) 0.40
SAS −0.001 (− 0.004–0.002) 0.62 0.000 (− 0.002–0.002) 0.78
Model R2 0.67 < 0.001 0.67 < 0.001
BMI body mass index, BP blood pressure, CVD cardiovascular disease, HDL high density lipoprotein, LDL low density lipoprotein, SAS standardised atheroma score,
SIMD Scottish Index of Multiple Deprivation
P-values < 0.05 highlighted in bold
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Fig. 3 Scatter plots of: a Compliance against SAS; b Compliance against LVMVR; c SAS against LVMVR
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useful to our understanding of cardiovascular disease, es-
pecially as we have focused on those with low-
intermediate cardiovascular risk before significant disease
has developed. Age, blood pressure, BMI, cholesterol and
smoking are all extremely well established risk factors and
are central to cardiovascular risk stratification for primary
prevention strategies [29, 30]. It is therefore interesting
that out of these risk factors, one (blood pressure) strongly
predicts arterial stiffening, one (smoking) predicts plaque
formation and another (BMI) predicts early cardiac re-
modeling. Given that all are strong risk factors for future
cardiovascular events this study suggests that they might
Table 4 Multivariable linear regression of (log) left ventricular mass to volume ratio
Men Women
B p B (95% CI) p
Age (years) −0.001 (− 0.001–0.00) 0.14 0.001 (0.00–0.002) 0.012
Heart rate (bpm) 0.00 (−0.001–0.001) 0.94 0.00 (− 0.001–0.00) 0.49
Systolic BP (mmHg) −0.002 (− 0.003- − 0.001) < 0.001 -0.001 (− 0.002- -0.001) < 0.001
Diastolic BP (mmHg) 0.003 (0.002–0.004) < 0.001 0.004 (0.003–0.004) < 0.001
BMI (kg/m2) 0.005 (− 0.003–0.012) 0.20 0.008 (0.002–0.013) 0.008
LDL-Cholesterol (mmol/L) 0.01 (−0.008–0.028) 0.30 − 0.008 (− 0.02–0.005) 0.23
HDL-Cholesterol (mmol/L) −0.001 (− 0.009–0.007) 0.79 0.003 (− 0.005–0.01) 0.46
Triglycerides (mmol/L) 0.015 (0.003–0.027) 0.012 0.018 (0.008–0.027) < 0.001
Smoking status 0.00 (−0.001–0.001) 0.85 −0.001 (− 0.001–0.00) 0.033
Pack years 0.003 (0.001–0.005) 0.001 0.001 (0.00–0.002) 0.028
Family history of CVD −0.003 (− 0.018–0.012) 0.70 0.002 (− 0.008–0.013) 0.69
SIMD 0.001 (− 0.001–0.004) 0.31 0.001 (− 0.001–0.003) 0.34
Compliance − 0.12 (− 0.16- -0.091) < 0.001 −0.12 (− 0.15- -0.086) < 0.001
SAS 0.005 (0.002–0.008) 0.002 0.002 (0.00–0.004) 0.062
Model R2 0.19 < 0.001 0.23 < 0.001
BMI body mass index, BP blood pressure, CVD cardiovascular disease, HDL high density lipoprotein, LDL low density lipoprotein, SAS standardised atheroma score,
SIMD Scottish Index of Multiple Deprivation
P-values < 0.05 highlighted in bold
Table 3 Backward multivariable linear regression of (Log) SAS
Men Women
B (95% CI) p B (95% CI) p
Age (years) 0.01 (0.007–0.013) < 0.001 0.008 (0.005–0.01) < 0.001
Heart rate (bpm) − 0.001 (− 0.003–0.002) 0.50 0.002 (− 0.001–0.004) 0.14
Systolic BP (mmHg) 0.002 (− 0.002–0.003) 0.41 0.002 (− 0.001–0.005) 0.17
Diastolic BP (mmHg) 0.000 (− 0.005–0.004) 0.87 -0.001 (− 0.005–0.002) 0.49
BMI (kg/m2) − 0.006 (− 0.013–0.001) 0.11 −0.003 (− 0.007–0.002) 0.22
LDL-Cholesterol (mmol/L) 0.02 (− 0.006–0.005) 0.12 0.027 (0.004–0.05) 0.022
HDL-Cholesterol (mmol/L) −0.03 (− 0.10–0.036) 0.35 0.010 (− 0.042–0.061) 0.72
Triglycerides (mmol/L) 0.02 (− 0.01–0.05) 0.19 0.007 (− 0.024–0.037) 0.67
Smoking status 0.038 (− 0.008–0.083) 0.10 −0.003 (− 0.041–0.035) 0.87
Pack years 0.003 (0.000–0.005) 0.022 0.004 (0.001–0.006) 0.002
Family history of CVD 0.04 (−0.016–0.097) 0.16 0.023 (−0.020–0.067) 0.29
SIMD −0.009 (− 0.019–0.001) 0.069 −0.003 (− 0.011–0.004) 0.40
Compliance 0.005 (− 0.12–0.13) 0.93 0.02 (− 0.10–0.14) 0.75
Model R2 0.16 < 0.001 0.11 < 0.001
BMI body mass index, BP blood pressure, CVD cardiovascular disease, HDL high density lipoprotein, LDL low density lipoprotein, SAS standardised atheroma score,
SIMD Scottish Index of Multiple Deprivation
P-values < 0.05 highlighted in bold
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all exert this risk through independent, separate mecha-
nisms although further longitudinal studies are required
to determine causation. Planned long term follow-up in
the TASCFORCE study will provide a key opportunity for
examining these further.
Our study suffers from several limitations. Whole body
angiography is a lumenographic technique, thus poten-
tially misses the earliest stages of atherosclerosis of fatty
streaks along the vascular lumen, as well as requiring
the administration of intravenous contrast [31]. However
no other technique currently exists for the simultaneous
acquisition of the whole body vasculature. Techniques
such as 3D–black-blood imaging, which can also be per-
formed without contrast, hold potential for this but to
date have only been utilized at single vessel sites [32]. In
addition it is arguable that since clinical manifestations
of atherosclerosis are secondary to plaque stenosis or
rupture rather than simple fatty streaks, that this is the
most clinically relevant association to examine. Partici-
pants were recruited based on a previous higher thresh-
old for the diagnosis of hypertension (145/90 mmHg)
and using the ATP-III criteria for cardiovascular disease
10 year risk, both of which were the reference standards
at the point of study design, but have been superseded
by more contemporaneous risk criteria and thresholds.
Thus our ‘healthy cohort’ included some participants
with what would now be considered hypertension,
potentially confounding associations between stiffness,
blood pressure and left ventricular remodeling, although
these persisted on multiple regression models. The pulse
pressure for compliance measurement was derived from
the brachial blood pressure measurement rather than
use of a central measurement or pulse wave analysis
which is a more accurate for the estimation of this [33].
However, estimation of TAC using blood pressure de-
rived from a brachial sphygmomanometer has consist-
ently proven to be an independent predictor of future
cardiovascular events in multiple cohorts [23, 34, 35],
and the observed associations between compliance
and cardiovascular risk factors are consistent with the
literature using both a peripheral pressure measure-
ment and PWV [36]. Finally the blood pressure was
not acquired contemporaneously with the stroke vol-
ume. Diurnal variation and situational variations are
known to affect blood pressure thus this could con-
found the calculation of compliance. The effect size of
this is likely to be small however as if significant vari-
ation between within scan blood pressure and without
scan blood pressure existed this would be most mani-
fest in an obviation or significant reduction of the as-
sociation between the compliance and blood pressure,
yet these variables demonstrated the strongest correl-
ation with one another on univariate and multivariate
analysis.
Conclusions
In conclusion systemic arteriosclerosis is associated with
LVremodelling but not atherosclerosis. Future efforts in
cardiovascular risk prevention should thus seek to address
both arteriosclerosis and atherosclerosis individually.
Additional file
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